{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:18:41Z","timestamp":1793834321650,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Donald P. Goldstein"},{"name":"MD Trophoblastic Tumor Registry Endowment"},{"name":"Dyett Family Trophoblastic Disease Research and Registry Endowment"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ygyno.2020.02.001","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T03:35:20Z","timestamp":1581046520000},"page":"372-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia"],"prefix":"10.1016","volume":"157","author":[{"given":"Izildinha","family":"Maest\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Nitecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Canedo Freitas","family":"Desmarais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross S.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9742","key":"10.1016\/j.ygyno.2020.02.001_bb0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(10)60280-2","article-title":"Gestational trophoblastic disease","volume":"376","author":"Seckl","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.001_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2012.07.116","article-title":"Current advances in the management of gestational trophoblastic diseases","volume":"128","author":"Berkowitz","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.02.001_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cancergen.2012.01.004","article-title":"The genetics of gestational trophoblastic disease: a rare complication of pregnancy","volume":"205","author":"Hoffner","year":"2012","journal-title":"Cancer Genet"},{"issue":"16","key":"10.1016\/j.ygyno.2020.02.001_bb0020","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMcp0900696","article-title":"Clinical practice. Molar pregnancy","volume":"360","author":"Berkowitz","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.001_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajog.2010.06.072","article-title":"Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia","volume":"204","author":"Lurain","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2020.02.001_bb0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0020-7292(03)90120-2","article-title":"Gestational trophoblastic neoplasia, FIGO 2000 staging and classification","volume":"83","author":"Ngan","year":"2003","journal-title":"International Journal of Gynaecology and Obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics"},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.001_bb0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0020-7292(02)00063-2","article-title":"FIGO staging for gestational trophoblastic neoplasia 2000","volume":"77","author":"FIGO Oncology Committee","year":"2002","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.001_bb0040","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E","article-title":"Risk and prognostic factors in trophoblastic neoplasia","volume":"38","author":"Bagshawe","year":"1976","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.001_bb0045","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ygyno.2012.03.039","article-title":"Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy","volume":"125","author":"Chapman-Davis","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.001_bb0050","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2013.05.017","article-title":"Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia","volume":"130","author":"Maest\u00e1","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.02.001_bb0055","first-page":"CD008891","article-title":"Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia","author":"Alazzam","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.001_bb0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2017.10.028","article-title":"Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center experience","volume":"148","author":"Maest\u00e1","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.001_bb0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ygyno.2016.10.001","article-title":"Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia","volume":"143","author":"Winter","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.02.001_bb0070","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.3802\/jgo.2018.29.e89","article-title":"Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide","volume":"29","author":"Kanno","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2020.02.001_bb0075","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.2002.07.166","article-title":"Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000","volume":"20","author":"McNeish","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"7\u20138","key":"10.1016\/j.ygyno.2020.02.001_bb0080","first-page":"283","article-title":"Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia","volume":"57","author":"Lurain","year":"2012","journal-title":"J Reprod Med."},{"issue":"5","key":"10.1016\/j.ygyno.2020.02.001_bb0085","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/IGC.0000000000001248","article-title":"Efficacy and safety of second-line 5-day Dactinomycin in case of methotrexate failure for gestational trophoblastic neoplasia","volume":"28","author":"Prouvot","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2020.02.001_bb0090","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/bjc.2012.462","article-title":"Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing cross hospital, 2000-2009","volume":"107","author":"Sita-Lumsden","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.001_bb0095","first-page":"341","article-title":"Actinomycin D as initial therapy of gestational trophoblastic disease. A reevaluation","volume":"39","author":"Goldstein","year":"1972","journal-title":"Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.ygyno.2020.02.001_bb0100","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/1097-0142(19871101)60:9<2173::AID-CNCR2820600910>3.0.CO;2-3","article-title":"Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the gynecologic oncology group","volume":"60","author":"Petrilli","year":"1987","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2020.02.001_bb0105","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/cncr.22118","article-title":"Gynecologic oncology group, phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study","volume":"107","author":"Covens","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2020.02.001_bb0110","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","article-title":"Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study","volume":"29","author":"Osborne","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.02.001_bb0115","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.6004\/jnccn.2019.0053","article-title":"Gestational trophoblastic neoplasia, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Abu-Rustum","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2020.02.001_bb0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijgo.12615","article-title":"Update on the diagnosis and management of gestational trophoblastic disease","volume":"143","author":"Ngan","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.001_bb0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/gyno.2001.6533","article-title":"Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance?","volume":"85","author":"Kohorn","year":"2002","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.001_bb0130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.hoc.2011.10.007","article-title":"Current management of gestational trophoblastic neoplasia","volume":"26","author":"Goldstein","year":"2012","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.001_bb0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0090-8258(86)90123-X","article-title":"Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease","volume":"23","author":"Berkowitz","year":"1986","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.02.001_bb0140","first-page":"355","article-title":"Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience","volume":"47","author":"Garrett","year":"2002","journal-title":"J Reprod Med"},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.001_bb0145","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0090-8258(90)90257-L","article-title":"Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study","volume":"39","author":"Homesley","year":"1990","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2020.02.001_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14656566.4.11.2005","article-title":"Pharmacotherapy of gestational trophoblastic disease","volume":"4","author":"Lurain","year":"2003","journal-title":"Expert. Opin. Pharmacother."},{"issue":"7\u20138","key":"10.1016\/j.ygyno.2020.02.001_bb0155","first-page":"279","article-title":"Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy","volume":"55","author":"Growdon","year":"2010","journal-title":"J Reprod Med"},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.001_bb0160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2019.03.005","article-title":"Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?","volume":"153","author":"Mora","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.001_bb0165","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2004.04.018","article-title":"Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia","volume":"94","author":"Chen","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2020.02.001_bb0170","first-page":"1424","article-title":"Serum hCG level and rising World Health Organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia","volume":"20","author":"Kang","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.02.001_bb0175","series-title":"Proceedings of the XX World Congress on GTD, Toronto, Canada","article-title":"Single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant low risk gestational trophoblastic neoplasia (GTN)","author":"Winter","year":"2019"},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.001_bb0180","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2019.03.005","article-title":"Can carboplatin or etoposide replace actinomycin -d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?","volume":"153","author":"Mora","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"6 Suppl 3","key":"10.1016\/j.ygyno.2020.02.001_bb0185","first-page":"3","article-title":"Oral mucositis in cancer therapy","volume":"2","author":"Sonis","year":"2004","journal-title":"J Support Oncol."},{"key":"10.1016\/j.ygyno.2020.02.001_bb0190","first-page":"e201","article-title":"Treatment of oral mucositis due to chemotherapy","volume":"8","author":"Chaveli-L\u00f3pez","year":"2016","journal-title":"J Clin Exp Dent"},{"issue":"10","key":"10.1016\/j.ygyno.2020.02.001_bb0195","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/cncr.28592","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"120","author":"Lalla","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2020.02.001_bb0200","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.001_bb0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2020.02.001_bb0210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pon.1245","article-title":"Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer, a literature review","volume":"17","author":"Lemieux","year":"2008","journal-title":"Psychooncology"},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.001_bb0215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2017.07.012","article-title":"Scalp hypothermia for preventing alopecia during chemotherapy, a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Rugo","year":"2018","journal-title":"Clin Breast Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:51:26Z","timestamp":1758772286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820300962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0090825820300962"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.02.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}